Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells

Satelli, Arun; Mitra, Abhisek; Cutrera, Jeffry J.; Devarie, Marcos; Xia, Xueqing; Ingram, Davis R.; Dibra, Denada; Somaiah, Neeta; Torres, Keila E.; Ravi, Vinod; Ludwig, Joseph A.; Kleinerman, Eugenie S.; Li, Shulin

doi:10.1158/0008-5472.can-13-1739

Cited by 141 publications

(199 citation statements)

References 14 publications

Supporting

Mentioning

188

Contrasting

Order By: Relevance

“…Furthermore, fluorescence microscopy of the sorted YFP + CTCs confirmed that the CTCs retained a mesenchymal morphology ( Figure 5F). In addition, flow cytometry further showed that YFP + CTCs are positive for high expression of cell-surface vimentin similar to that of primary sarcoma cells (Supplemental Figure 5C), a finding that is in agreement with a recent study showing that vimentin might serve as an exclusive marker on sarcoma CTCs (17). Of importance, PCR analysis of genomic DNA from these YFP + CTCs clearly demonstrated efficient recombination of KPY alleles with the presence of WT miR-182 in these cells ( Figure 5G), indicating that the YFP + CTCs are derived from KPY sarcomas.…”

Section: Mir-182 Is Elevated In a Subset Of Metastatic Sarcomassupporting

confidence: 90%

MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes

et al. 2014

View full text Add to dashboard Cite

Section: Mir-182 Is Elevated In a Subset Of Metastatic Sarcomassupporting

confidence: 90%

MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes

et al. 2014

View full text Add to dashboard Cite

“…Detection of vimentin is currently being explored as a biomarker in cancer (41,(83)(84)(85), and ongoing studies are currently being conducted to correlate the presence of oxidized proteins, like oxidized LDL to aging and organismal frailty (86,87). Here, we have developed a sandwich ELISA to detect secreted MDAmodified vimentin using our 9H4 antibody in the context of profiling cellular senescence in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody

Frescas

Roux

Aygun‐Sunar

et al. 2017

Proc. Natl. Acad. Sci. U.S.A.

113

103

View full text Add to dashboard Cite

Studying the phenomenon of cellular senescence has been hindered by the lack of senescence-specific markers. As such, detection of proteins informally associated with senescence accompanies the use of senescence-associated β-galactosidase as a collection of semiselective markers to monitor the presence of senescent cells. To identify novel biomarkers of senescence, we immunized BALB/c mice with senescent mouse lung fibroblasts and screened for antibodies that recognized senescence-associated cell-surface antigens by FACS analysis and a newly developed cell-based ELISA. The majority of antibodies that we isolated, cloned, and sequenced belonged to the IgM isotype of the innate immune system. In-depth characterization of one of these monoclonal, polyreactive natural antibodies, the IgM clone 9H4, revealed its ability to recognize the intermediate filament vimentin. By using 9H4, we observed that senescent primary human fibroblasts express vimentin on their cell surface, and MS analysis revealed a posttranslational modification on cysteine 328 (C328) by the oxidative adduct malondialdehyde (MDA). Moreover, elevated levels of secreted MDA-modified vimentin were detected in the plasma of aged senescence-accelerated mouse prone 8 mice, which are known to have deregulated reactive oxygen species metabolism and accelerated aging. Based on these findings, we hypothesize that humoral innate immunity may recognize senescent cells by the presence of membrane-bound MDA-vimentin, presumably as part of a senescence eradication mechanism that may become impaired with age and result in senescent cell accumulation.aging | oxidative posttranslational modifications | biomarker | SAMP8 | malondialdehyde

show abstract

“…This antibody was proven to be specific for vimentin bound to cancer cell surface. It did not show any binding toward macrophages, endothelial cells, neutrophils, platelets or apoptotic T lymphocytes [21].…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 86%

Liquid Biopsy in Liquid Tumors

Ranuncolo¹

2017

JCT

View full text Add to dashboard Cite

The availability of a minimally invasive patient simple, capable of providing tumor information, represents a valuable clinical tool. The liquid biopsy has the potential to achieve this need. Circulating cell free DNA (ccfDNA), other circulating nucleic acids such as microRNA and circulating tumor cells (CTCs), can be obtained from a peripheral blood sample. Liquid biopsy has been particularly studied in solid tumors, specially of the epitelial origin, such as a pancreatic carcinoma and advanced breast cancer. It has been considerably less applied to the study of non-solid tumors. It represents an important source for diagnosis, prognosis and predictive information. Also it is suitable to evaluate response to therapy and drugs pharmacokinetics. It provides a unique opportunity to evaluate the disease evolution in serial blood samples collection, otherwise difficult to obtain. Liquid biopsy can be rehearsed using different circulating biological fluids such as whole blood, serum, plasma and lymph, as well as, non-circulating fluids such as urine, feces, saliva, bile and accumulated pathological fluids such as ascites. This review summarizes the current status of circulating material analysis in non-solid tunors. It is specially focused on Hodgkin Lymphoma and among Non-Hodgkin Lymphoma, it refers particularly to Diffuse Large B cell Lymphoma, the most common aggressive Non-Hodgkin Lymphoma derived from germinal center B-cells in adults. It further discusses the benefit of liquid biopsy in oncohemtaological diseases and potential clinical applications.

show abstract

Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells

Cited by 141 publications

References 14 publications

MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes

MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes

Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody

Liquid Biopsy in Liquid Tumors

Contact Info

Product

Resources

About